Navigation Links
Sinovac Reports Unaudited First Quarter 2012 Financial Results
Date:5/15/2012

g income (loss)(8,180,522)(3,528,196)Interest and financing expenses (214,320)(69,697)Interest income597,671.00145,374.00Loss on disposal of equipment-(7,704)Other income (expenses)118,078105,969Income (loss)  before income taxes and non-controlling interests(7,679,093)(3,354,254)Income tax recovery (expenses) 2,902(310,422)Consolidated net loss(7,676,191)(3,664,676)Less:  loss attributable to non-controlling interests2,063,136869,720Net loss attributable to stockholders$(5,613,055)$(2,794,956)Net loss$

(7,676,191)

$

(3,664,676)Other comprehensive income Foreign currency translation adjustment646,783839,567Total comprehensive loss(7,029,408)(2,825,109)Less: comprehensive loss attributable to non-controlling interests 1,979,589728,475Comprehensive loss attributable to stockholders$

(5,049,819)

$

(2,096,634)Loss per share
- basic$

(0.10)

$

(0.05)- diluted$

(0.10)

$

(0.05)Weighted average number of shares of common stock outstanding - Basic 54,608,91954,444,077- Diluted54,608,91954,444,077 

 

 

SINOVAC BIOTECH LTD.Incorporated in Antigua and BarbudaConsolidated Statements of Cash FlowsThree months ended March 31, 2012 and 2011(Expressed in U.S. Dollars)Three months endedMarch 3120122011Cash flows used in operating activities  Net income (loss)

$

(7,676,191)

$

(3,664,676) 

  Adjustments to reconcile net income to net cash

   provided by operating activities: - deferred income taxes(2,902)310,422 - stock-based compensation80,17532,662 - inventory provision85,864- - Provision for (recovery of)  doubtful accounts-- - write-down of equipment and loss on disposal-7,704  - unrealized foreign exchange gain(210,581)- - research and development expenditures qualified for&
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
2. Sinovac to Host Conference Call to Report Fourth Quarter 2011 Unaudited Financial Results
3. Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement
4. Sinovac to Present at 23rd Annual Piper Jaffray Health Care Conference and HK/China Mini Conference 2011 (Healthcare)
5. /C O R R E C T I O N -- Sinovac Biotech Ltd./
6. Sinovac Reports Unaudited Third Quarter 2011 Financial Results
7. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
8. Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
9. Sinovac Reports Unaudited Second Quarter 2011 Financial Results
10. Sinovac Announces Management Changes
11. Sinovac Holds 2011 Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
(Date:9/23/2014)... Calif. , Sept. 23, 2014  Savant ... today confirmed the initiation of human safety testing ... of addiction. A single dose of 18-MC, administered ... study conducted by Savant,s South American partner, was ... drug. Savant HWP plans to develop 18-MC as ...
Breaking Medicine Technology:Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... March 15, 2011 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation, bleeding and disorders ... for the fourth quarter and year ended December 31, ... for the three months ended December 31, 2010 were ...
... Pharmacy Benefit Consulting, the nation,s leading Pharmacy Benefit ... their clients. On February 16th, ARMSRx ... Lumber.  It was recommended and modeled by ARMSRx last ... making some simple changes.  The results speak for themselves. ...
Cached Medicine Technology:Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 2Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 3Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 4Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 5Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 6ARMSRx and 84 Lumber Hammer Down Rx Costs...Again 2
(Date:9/23/2014)... Mich. They are common suggestions to remedy stress: You ... Get out and see people. , Turns out ... better a lot better a new large scale ... lower depression, less perceived stress and enhanced mental health and ... Michigan, with partners from De Montfort University, James Hutton Institute, ...
(Date:9/23/2014)... ANGELES (September 23, 2014) Laparoscopic cholecystectomy, a minimally ... the most common abdominal surgeries in the U.S. Yet ... to the procedure with some moving patients quickly into ... online Monday in the American Journal of Surgery ... regular working hours rather than rushing the patients into ...
(Date:9/23/2014)... living things function comes from knowledge of structuresatomic details ... receptors that are docking stations for viruses and messenger ... carry genetic blueprints for building cellular machinery, to name ... structural details, a new grant just awarded by the ... of Energy (DOE) will fund the operation of a ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry expert ... is a 13-year veteran in the school, commercial and transit ... Bus Sales of Colton, California. While with A-Z Mr. Reynolds ... line revenues, profit and market penetration by double digits. , ... all-electric or plug-in hybrid vehicle conversions. They have converted ...
(Date:9/23/2014)... the European Journal of Cancer presents detailed ... the 1st EORTC Cancer Survivorship Summit held this past ... and more personalized multimodal treatments has boosted survival rates ... and rapidly increasing number of cancer survivors. Despite this ... broad spectrum of late adverse treatment effects and some ...
Breaking Medicine News(10 mins):Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:Study finds gallbladder surgery can wait 2Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2
... disease are there, researchers say , WEDNESDAY, Oct. 24 (HealthDay ... show early signs of heart disease -- similar to that ... by a team at Washington University School of Medicine, St. ... the children had undergone cardiac ultrasound to check on symptoms ...
... break-through new way of ... taking daily dose of glucosamine, SAN FRANCISCO, Oct. 24 ... wants to help,people keep their joints hydrated and moving smoothly.* The ... Joint Juice products: -- Original Joint Juice: ready-to-drink juice-based dietary ...
... ), the,global leader in the development, manufacture and supply ... today that it,will broadcast a third quarter 2007 earnings ... 2007 at 10:00 a.m. EDT. The call will,last approximately ... the opportunity to listen to,the conference call live at ...
... FRANCISCO While some targeted therapies drugs ... pathways occurring within cancer cells work well by ... when teamed with other targeted and conventional therapies. ... Molecular Targets and Cancer Therapeutics, multiple-target applications of new ...
... Out of Pocket Expenses ... for Medical Foods, ... BMRN) announced today that it has,provided a $250,000 grant to the ... program for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds ...
... 24 NutraCea (OTC Bulletin,Board: NTRZ), a health ... bran (SRB) nutrient research and technology whose products ... benefits for,humans and animals announced today that it ... relations services and an expanded,communications program among the ...
Cached Medicine News:Health News:Obesity Can Hurt Kids' Hearts 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3
... automated semen analysis, with accurate, consistent, reliable ... Automation provides standardization and ease of use ... analysis. SPERMALITE is a new-generation automated semen ... analysis, and a hard -copy analysis report ...
Stainless Steel. Sterile. 2 pieces/box...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
... The first FDA-cleared third-generation allergy test , ... blood testing. It provides quantitative determination of ... excellent precision, accuracy and lot-to-lot reproducibility. The ... hour to help you identify, monitor and ...
Medicine Products: